Avantor Results Presentation Deck

Q2 highlights Strong business momentum Robust core business growth supported by favorable end market trends COVID-19 tailwinds in line with guidance, driven by vaccine contributions Above plan performance across all key financial metrics Executing on our growth strategy - Closed acquisition of Ritter, increasing our proprietary content for critical life science workflows Ongoing execution of AMEA growth strategy Acquired RIM Bio, establishing single use manufacturing in China Received top bioprocessing supplier awards at Biologics Manufacturing Korea 2021 Completed multiple capacity expansions in raw materials and single use manufacturing Proactively extended our long-standing agreement with the BIO consortium through 2029 Published inaugural sustainability report Looking ahead Expected continuation of growth momentum and execution Raising full year outlook for revenue, adjusted EBITDA, adjusted EPS and Free Cash Flow avantor™ 3

View entire presentation